Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $7.00 | Hold | Truist |
| 4/10/2025 | $6.00 | Equal Weight → Underweight | Barclays |
| 12/11/2024 | $30.00 → $23.00 | Buy → Neutral | Citigroup |
| 12/6/2024 | $28.00 → $25.00 | Outperform → Neutral | Robert W. Baird |
| 9/25/2024 | $25.00 → $21.00 | Buy → Hold | Jefferies |
| 8/8/2024 | $31.00 → $27.00 | Outperform → In-line | Evercore ISI |
| 7/24/2024 | $30.00 | Equal Weight | Barclays |
| 6/6/2024 | $28.00 | Neutral | Goldman |
Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00
Barclays downgraded Fortrea from Equal Weight to Underweight and set a new price target of $6.00
Citigroup downgraded Fortrea from Buy to Neutral and set a new price target of $23.00 from $30.00 previously
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) -- The Society for Clinical Research Sites (SCRS) and Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea's sponsorship of the SCRS Collaborate Forward working group. Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficie
SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have
DURHAM, N.C., July 11, 2024 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that Robert "Bobby" Parks has been appointed as chief accounting officer (CAO), responsible for Fortrea's accounting function, including financial reporting, risk, controls and compliance in accordance with applicable standards, laws and regulations. "We are pleased to welcome Bobby to the Fortrea team, bringing his broad and deep experience from CROs and other fast-paced environments," said Fortrea Chief Financial Officer Jill McConnell. "Bobby has a track record of managing Sarbanes-Oxley Act requirements and internal controls, including for CROs,
For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai
DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank
DURHAM, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced it has been recognized as a "Leader" for pharmacovigilance (PV) operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix® Assessment 2025. Fortrea's top position was recognized in both pre-and post-approval PV operations in Everest Group's proprietary framework, which assesses market impact along with vision and capability. "Fortrea's mission is to bring life-changing treatments to patients faster, and we have translated our profound commitment to patients into recognized leadership in pharmacovigilance," said Mark Morais, c
For the three months ended March 31, 2025, from continuing operations: Revenues of $651.3 millionGAAP net loss of $(562.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $30.3 millionGAAP and adjusted net (loss) income per diluted share of $(6.25) and $0.02, respectivelyBook-to-bill ratio of 1.02x, resulting in 1.14x book-to-bill for the trailing 12 months DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported financial results for the first quarter ended March 31, 2025. "Fortrea's first quarter performance represents a solid start to 2025," sai
DURHAM, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that Thomas Pike is stepping down from his role as Fortrea's Chief Executive Officer and as Chairman of its Board. Fortrea's Lead Independent Director, Peter M. Neupert, will serve as Interim Chief Executive Officer and Board Chair, beginning May 13, 2025. As part of a succession planning process, an executive search is already at an advanced stage. Mr. Pike has entered into a consulting agreement with the Company to serve as a resource to its leadership team through the transition. "On behalf of Fortrea's Board, I would like to thank
DURHAM, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2025 financial results before the market opens on Monday, May 12, 2025. Fortrea will host a conference call at 9:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast link.
SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)
SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)
SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
4 - Fortrea Holdings Inc. (0001965040) (Issuer)
SCHEDULE 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)
10-Q - Fortrea Holdings Inc. (0001965040) (Filer)
SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)